Merck Signs Cancer Deal with Spanish National Cancer Research Centre - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Merck Signs Cancer Deal with Spanish National Cancer Research Centre


Merck Serono, the biopharmaceutical division of Merck, has entered into an agreement on cancer drug development with the Spanish National Cancer Research Centre (CNIO) in Madrid. The agreement will build upon CNIO research discoveries with the aim of translating its research into new treatment options for cancer patients.

Under the terms of the license agreement, Merck receives exclusive rights to develop and commercialize CNIO’s new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase. Merck will in turn make an initial payment to CNIO along with other potential income of up to € 19 million, as well as royalties on net sales. The agreement encompasses the licensing of two series of ATR inhibitors, as well as a screening platform to validate the compounds, which have currently reached an advanced preclinical stage.

ATR kinase plays an important role in the response to DNA damage and in facilitating cell survival. Due to the fact that tumor cells accumulate more DNA damage than healthy cells, blocking ATR kinase activity with selective inhibitors appears to be a strategy worth investigating further for specific tumor types.

Source: Merck Serono

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here